Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Conference Coverage

Conference Coverage
Cost-Effectiveness of Lisocabtagene Maraleucel vs Axicabtagene Ciloleucel for Relapsed or Refractory LBCL
12/16/2021

Marta Rybczynski

Marta Rybczynski
Lisocabtagene maraleucel may be cost-effective vs axicabtagene ciloleucel for relapsed or refractory LBCL from a commercial US payer perspective, according to a study presented at 2021 ASH Annual Meeting.
Lisocabtagene maraleucel may be cost-effective vs axicabtagene ciloleucel for relapsed or refractory LBCL from a commercial US payer perspective, according to a study presented at 2021 ASH Annual Meeting.
Lisocabtagene maraleucel may be...
12/16/2021
Journal of Clinical Pathways
Conference Coverage
First-Line Venetoclax Plus Azacitidine vs Intensive Chemotherapy for Patients With AML in the Real-World Setting
12/11/2021

Janelle Bradley

Janelle Bradley
In the real-world setting, use of intensive chemotherapy was more common than venetoclax plus azacitidine for patients aged 60-75 years with AML.
In the real-world setting, use of intensive chemotherapy was more common than venetoclax plus azacitidine for patients aged 60-75 years with AML.
In the real-world setting, use...
12/11/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Treatment Patterns and Decision-Making for Patients With MM in the United States
12/08/2021

Janelle Bradley

Janelle Bradley
Study results presented at the 2021 ASH Annual Meeting provided valuable real-world data on current treatment patterns and decision-making for patients with MM.
Study results presented at the 2021 ASH Annual Meeting provided valuable real-world data on current treatment patterns and decision-making for patients with MM.
Study results presented at the...
12/08/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
Safety and Cost-Effectiveness of CAR-T Therapy in the Outpatient vs Inpatient Setting
12/08/2021

Janelle Bradley

Janelle Bradley
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the...
12/08/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Safety, Efficacy of Belantamab Mafodotin for Relapsed/Refractory MM
12/08/2021

Janelle Bradley

Janelle Bradley
In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with MM to those seen in clinical trials.
In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with MM to those seen in clinical trials.
In the real-world setting,...
12/08/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Incidence of Thromboembolic Events in Patients With Metastatic Breast Cancer Treated With Ribociclib
12/07/2021

Janelle Bradley

Janelle Bradley
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.
Study findings show patients...
12/07/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
Care Team Burden Impact on Treatment Selection for CLL and Lymphoid Malignancies
12/07/2021

Marta Rybczynski

Marta Rybczynski
Study findings suggest domain-specific appraisal of electronic communication portals can improve health care delivery and intervention and maximize patient-centered care while decreasing therapy-related health care team burden.
Study findings suggest domain-specific appraisal of electronic communication portals can improve health care delivery and intervention and maximize patient-centered care while decreasing therapy-related health care team burden.
Study findings suggest...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Budget Impact of Blood-Based Biomarker Assay in Patients With Metastatic Breast Cancer
12/07/2021

Janelle Bradley

Janelle Bradley
Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...
Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...
Use of a blood-based biomarker...
12/07/2021
Journal of Clinical Pathways
Conference Coverage
Biomarker Testing and Alpelisib Treatment Patterns for Metastatic Breast Cancer in the Community Oncology Setting
12/07/2021

Janelle Bradley

Janelle Bradley
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.
A study presented at the 2021...
12/07/2021
Journal of Clinical Pathways

Advertisement

Conference Coverage
Oncologists’ Perspectives on Patient-centered Dosing for Metastatic Breast Cancer
12/06/2021

Janelle Bradley

Janelle Bradley
Medical oncologists reported that a high percentage of patients experience distressing toxicity, a need for acute care, and dose interruptions with standard delivery of therapy for metastatic breast cancer.
Medical oncologists reported that a high percentage of patients experience distressing toxicity, a need for acute care, and dose interruptions with standard delivery of therapy for metastatic breast cancer.
Medical oncologists reported...
12/06/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use